Fresenius raises 2026 earnings outlook on strong Q2 results
Fresenius SE & Co. KGaA reported that Q2 2026 organic revenue grew 5 % to €5.86 billion and EBIT rose 10 % to €719 million in constant currency. The group upgraded its full‑year 2026 core EPS growth guidance to 10‑15 % from the previous 5‑10 % range.
Fresenius Medical Care AG & Co. KGaA posted the same‑quarter organic revenue increase of 5 % and a 23 % rise in operating income, while completing an initial €1 billion share‑repurchase programme ahead of schedule and launching a second €1 billion programme. U.S. same‑market treatment growth fell 0.9 % due to a referral‑execution gap, whereas international growth rose 0.8 %.
The company also announced that Cassie McLean will become CEO of the Care Delivery operating segment of FMC on 1 August 2026, succeeding Craig Cordola. The appointment is part of broader organisational changes aimed at improving clinic performance.
Entities: Cassie McLean · Craig Cordola · Fresenius Medical Care AG · Fresenius Medical Care AG & Co. KGaA · Fresenius SE & Co. KGaA · Helen Giza · Michael Sen
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 3 SOURCES] Fresenius Q2 2026 organic revenue grew 5% to €5.864 billion. (source)
- [● 3 SOURCES] Fresenius upgraded its FY 2026 constant‑currency core EPS growth guidance to 10‑15% from 5‑10%. (source)
- [○ 1 SOURCE] U.S. same‑market treatment growth at FMC declined 0.9% in Q2 due to a referral execution gap. (source)
- [○ 1 SOURCE] FMC completed a €1 billion share‑repurchase programme ahead of schedule and started a second €1 billion programme. (source)
- [○ 1 SOURCE] Fresenius Medical Care Q2 2026 organic revenue grew 5% and operating income rose 23% constant‑currency. (source)
- [○ 1 SOURCE] FMC's FME25+ transformation programme generated €67 million of sustainable savings in Q2. (source)
- [○ 1 SOURCE] Cassie McLean was appointed CEO of FMC's Care Delivery segment effective 1 August 2026, succeeding Craig Cordola. (source)
- [● 3 SOURCES] Fresenius Q2 2026 EBIT was €719 million, up 10% constant‑currency. (source)